Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients

Clinical and Experimental Metastasis

Volumn 29, Issue 7, 2012, Pages 801-805

  Mozzillo, Nicola ^a   Ascierto, Paolo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Circulating T cells; Distant metastasis; Interferon; Melanoma

Indexed keywords

ALPHA2B INTERFERON;

ADULT; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INDUCTION CHEMOTHERAPY; LYMPHOCYTE COUNT; MALE; MELANOMA; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; TREATMENT DURATION;

ADULT; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; NEOADJUVANT THERAPY; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 84868202435     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-012-9504-2     Document Type: Conference Paper

References (17)

1. Fecher LA, Flaherty KT (2009) Where are we with adjuvant therapy of stage III and IV melanoma in 2009? J Natl Compr Cancer Netw 7:295-304
2. Wheatley K, Ives N, Eggermont A, et al. (2007) Interferon-a as adjuvant therapy for melanoma: An individual patient data metaanalysis of randomised trials. J Clin Oncol. ASCO annual meeting proceedings Part I 25: Abstract 8526, 2007 (18S (June 20 Supplement))
3. Mocellin S, Pasquali S, Rossi CR, et al. (2010) Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J Natl Cancer Inst
4. de La Salmoniere P, Grob JJ, Dreno B et al (2000) White blood cell count: A prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma. Clin Cancer Res 6:4713-4718
5. Stuckert JJ II, Tarhini AA, Lee S, et al (2007) Interferon alfainduced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696. J Clin Oncol (Meet Abstr) 25:8506
6. Gogas H, Ioannovich J, Dafni U et al (2006) Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 354:709-718
7. Moschos SJ, Edington HD, Land SR et al (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24:3164-3171
8. Ascierto PA, Kirkwood JM (2008) Adjuvant therapy of melanoma with interferon: Lessons of the past decade. J Transl Med 6:62
9. Simons DL, Lee G, Kirkwood JM et al (2011) Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med 9:52
10. Wang W, Edington HD, Rao UN et al (2007) Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res 13:1523-1531
11. Wang W, Edington HD, Rao UN et al (2008) Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: Modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 14:8314-8320
12. Hiura T, Kagamu H, Miura S et al (2005) Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression. J Immunol 175:5058-5066
13. Takahashi T, Tagami T, Yamazaki S et al (2000) Immunologic self-tolerance maintained by CD25? CD4? regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303-310
14. Shimizu J, Yamazaki S, Takahashi T et al (2002) Stimulation of CD25? CD4? regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3:135-142
15. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061
16. Gabriel EM, Lattime EC (2007) Anti-CTL-associated antigen 4: Are regulatory T cells a target? Clin Cancer Res 13:785-788
17. Viguier M, Lemaitre F, Verola O et al (2004) Foxp3 expressing CD4? CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444-1453